Results: 67

Changes in the ganglion cell complex thickness after anti-VEGF treatment for diabetic macular edema

Arq. bras. oftalmol; 83 (5), 2020
ABSTRACT Purpose: To assess tomographic ganglion cell complex changes in patients with diabetic macular edema treated with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF). Methods: We analyzed data from 35 eyes of 35 previously untreated patients in whom diabetic macular ...

Estrategias de tratamiento para el edema macular diabético
Treatment strategies for diabetic macular edema

Rev. cuba. oftalmol; 33 (3), 2020
RESUMEN Se hace una revisión bibliográfica acerca del tratamiento que se utiliza en el edema macular clínicamente significativo. Esta es la primera causa de mala visión en los pacientes con diabetes mellitus. Entre las líneas de tratamiento tenemos los antiangiogénicos con sus variantes, los estero...

The usefulness of systemic inflammatory markers as diagnostic indicators of the pathogenesis of diabetic macular edema

Arq. bras. oftalmol; 83 (4), 2020
ABSTRACT Purpose: To investigate the usefulness of systemic inflammatory markers [i.e., white blood cell and platelet counts, mean platelet volume, and their ratios] as diagnostic markers of the pathogenesis of diabetic macular edema. Methods: The study cohort included 80 diabetic macular edema patient...

Generalidades del tratamiento del edema macular diabético y la indicación de las estatinas
Generalities of the Treatment of Diabetic Macular Edema and the Use of Statins

Rev. cuba. endocrinol; 31 (2), 2020
RESUMEN Introducción: Cualquiera de las formas de retinopatía diabética se puede acompañar de la presencia de edema macular diabético. El uso de las estatinas en personas con diabetes mellitus y edema macular diabético se ha sugerido como una medida terapéutica. Objetivo: Describir de manera g...

Cystoid macular edema secondary to intraocular lens sub-luxation and iris perforation by iol haptic

Rev. bras. oftalmol; 79 (4), 2020
Abstract We present a case of 50-years-old, man with vision loss, dysmorphopsia and micropsy in the right eye with for 6 months. Ocular history included uncomplicated cataract surgery 10 years before. Best corrected visual acuity was 20/100 in the right eye and 20/20 in the left eye. Anterior segment OD ...

Incidence of clinical and subclinical macular edema in patients submitted to phacoemulsification in a university health service

ABCS health sci; 45 (Supl. 3), 2020
INTRODUCTION: The incidence of cystoid macular edema (CME) after cataract surgery varies substantially and depending on the diagnostic method used. In addition, other factors that influence the incidence of CME are the technique of surgery and the associated comorbidities. OBJECTIVE: The aim of the prese...

Dexamethasone intravitreal implant for macular edema: a pilot study in a public health center

ABCS health sci; 45 (Supl. 3), 2020
INTRODUCTION: Macula edema consists in one of the most common causes of visual impairment. OBJECTIVE: To evaluate the safety and efficacy of continuous release of 0.7 mg dexamethasone (using implantable device) for treatment of macular edema. METHODS: Cross-sectional observational study of 16 patients tr...

Diabetic macular edema: a literature review

ABCS health sci; 45 (Supl. 3), 2020
Diabetic Macular Edema is a major cause of visual impairment in economically active population, being responsible for a significant impact in quality of life in the affected population, as well as high costs to the health care system. Over decades, some studies have compared treatments using Laser, Anti-...

Dexamethasone intravitreal implant in the crystalline lens: a case report

Arq. bras. oftalmol; 83 (3), 2020
ABSTRACT This report describes the therapeutic effects and outcomes of an accidental injection of an intralenticular sustained-release dexamethasone implant (Ozurdex®) in three patients with diabetic macular edema. All three patients underwent accidental injections of sustained-release intravitreal dexa...

Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation

Arq. bras. oftalmol; 83 (2), 2020
ABSTRACT Gyrate atrophy is a rare metabolic autosomal recessive disorder caused by ornithine aminotransferase enzyme deficiency that leads to characteristic progressive, degenerative chorioretinal findings. Patients complain mostly of low vision, night blindness, and peripheral vision loss. Posterior sub...